Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection
JAMA (2022) - Comment
doi: 10.1001/jama.2021.24939  issn: 0098-7484  pubmed: 35029629  issn: 1538-3598 

Meagan P. O’Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa, Peijie Hou, Kuo-Chen Chan, Bret J. Musser, Katharine J. Bar, Ruanne V. Barnabas, Dan H. Barouch, Myron S. Cohen, Christopher B. Hurt, Dale R. Burwen, Mary A. Marovich, Elizabeth R. Brown, Ingeborg Heirman, John D. Davis, Kenneth C. Turner, Divya Ramesh, Adnan Mahmood